Seek Returns

DHR vs. RVTY: Danaher vs. Revvity Stock Comparison

How do Danaher (DHR) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Danaher (DHR) and Revvity (RVTY) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Danaher (DHR) and Revvity (RVTY)
Profile ItemDHRRVTY
NameDanaher Corp.Revvity Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
GICS Sub-IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
Market Capitalization161.86 billion USD17.31 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateDecember 29, 1978February 21, 1973
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

DHR
RVTY
GSPC
Loading price history…
Danaher (DHR) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Danaher (DHR) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Danaher (DHR) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Danaher (DHR) and Revvity (RVTY)
MetricDHRRVTY
Total Return (1Y)11.88%76.75%
Total Return (3Y, Annualized)6.67%24.22%
Total Return (5Y, Annualized)-2.05%-1.48%

Risk Profile

Drawdown History

DHR
RVTY
GSPC
Loading price history…
Danaher (DHR) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Danaher (DHR) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Danaher (DHR) and Revvity (RVTY)
MetricDHRRVTY
Volatility (1Y, Annualized)30.61%40.22%
Beta (5Y)0.761.07
Max Drawdown (5Y)-43.31%-59.01%
Avg. Volume (3M)3.94M1.89M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
DHR and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Danaher (DHR) and Revvity (RVTY)
MetricDHRRVTY
Sharpe Ratio (1Y)0.251.80
Sortino Ratio (1Y)0.352.90

Profitability

ROE (TTM)

Danaher (DHR) at 8.19% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for DHR.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max
109.18%
DHR
8.19%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max
109.18%
Q3
6.23%
RVTY
3.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both Danaher (DHR) at 16.91% and Revvity (RVTY) at 8.61% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.91%

Max
18.05%
DHR
16.91%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max
18.05%
RVTY
8.61%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Danaher (DHR) at 21.13% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.13%

Max
83.12%
DHR
21.13%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max
83.12%
RVTY
17.06%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Danaher (DHR) and Revvity (RVTY)
MetricDHRRVTY
ROE (TTM)8.19%3.45%
ROA (TTM)4.06%2.54%
Net Margin (TTM)16.91%8.61%
Operating Margin (TTM)21.13%17.06%
Gross Margin (TTM)59.36%55.91%

Growth

Revenue Growth

Both Danaher (DHR) at 2.90% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Danaher (DHR) at -4.54% and Revvity (RVTY) at -5.91% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Danaher (DHR) and Revvity (RVTY)
MetricDHRRVTY
Revenue Growth (YoY)2.90%3.67%
Revenue Growth (3Y CAGR)-2.67%-4.82%
EPS Growth (YoY)-4.54%-5.91%
EPS Growth (3Y CAGR)-19.44%-23.26%

Financial Strength

Current Ratio (MRQ)

Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while Danaher (DHR) at 1.63 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for DHR.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.63

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
DHR
1.63
Min
0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max
25.13
Q3
12.13
Median
5.52
RVTY
2.65
Q1
2.47
Min
0.10
Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Danaher (DHR) at 0.52 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.52

Max
1.42
Q3
0.65
DHR
0.52
Median
0.15
Q1
0.02
Min
0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
RVTY
0.38
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Danaher (DHR) and Revvity (RVTY)
MetricDHRRVTY
Current Ratio (MRQ)1.632.65
Debt / Equity (MRQ)0.520.38
Net Debt / EBITDA2.682.43

Dividends

Dividend Yield (TTM)

Both Danaher (DHR) at 0.67% and Revvity (RVTY) at 0.19% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67%

DHR
0.67%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY
0.19%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Danaher (DHR) at 25.17% and Revvity (RVTY) at 13.40% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.17%

DHR
25.17%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY
13.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Danaher (DHR) and Revvity (RVTY)
MetricDHRRVTY
Dividend Yield (TTM)0.67%0.19%
Dividend Payout Ratio (TTM)25.17%13.40%

Valuation

P/E Ratio (TTM)

Danaher (DHR) at 38.12 is near its industry’s usual P/E ratio, while Revvity (RVTY) at 68.94 sits in the richer quartile — RVTY needs stronger growth or earnings quality to justify the premium.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.12

Max
85.34
Q3
43.46
DHR
38.12
Median
26.69
Q1
13.30
Min
0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max
85.34
RVTY
68.94
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Danaher (DHR) at 6.32 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.32

Max
58.18
Q3
25.77
Median
7.30
DHR
6.32
Q1
3.01
Min
0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max
58.18
Q3
25.77
Median
7.30
RVTY
5.88
Q1
3.01
Min
0.01
Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Danaher (DHR) at 3.02 and Revvity (RVTY) at 2.39 are valued close to their industries’ norm against book — neither stands out from peers.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.02

Max
13.53
Q3
6.54
Median
3.25
DHR
3.02
Q1
1.69
Min
-5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max
13.53
Q3
6.54
Median
3.25
RVTY
2.39
Q1
1.69
Min
-5.59
Loading chart…
Danaher (DHR) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Danaher (DHR) and Revvity (RVTY)
MetricDHRRVTY
P/E Ratio (TTM)38.1268.94
P/S Ratio (TTM)6.325.88
P/B Ratio (MRQ)3.022.39
Free Cash Flow Yield (TTM)2.93%3.62%